Skip to Content
Morningstar

Ultragenyx Pharmaceutical Inc RARE

Morningstar Rating
Unlock
Stock XNAS Rating as of
$42.54 −1.48 (3.36%)
View Full Chart
As of Delayed Price Post-Trading: $42.54 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
RARE is trading within a range we consider fairly valued.
Price
$44.03
Fair Value
$55.55
Uncertainty
Very High
1-Star Price
$12.27
5-Star Price
$43.71
Economic Moat
Yvj
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RARE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$44.02
Day Range
$42.51–44.32
52-Week Range
$31.52–54.98
Bid/Ask
$42.51 / $45.07
Market Cap
$3.54 Bil
Volume/Avg
714,710 / 700,874

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
7.46
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
1,276
Website
https://www.ultragenyx.com

Comparables

Valuation

View More
Metric
RARE
NBIX
SRPT
Price/Earnings (Normalized)
 —27.82—
Price/Book Value
 13.166.1414.05
Price/Sales
 7.467.439.57
Price/Cash Flow
 —38.78—
Price/Earnings
RARE
NBIX
SRPT

Financial Strength

Metric
RARE
NBIX
SRPT
Quick Ratio
 2.322.253.23
Current Ratio
 2.612.453.95
Interest Coverage
 −8.6273.20−26.54
Quick Ratio
RARE
NBIX
SRPT

Profitability

Metric
RARE
NBIX
SRPT
Return on Assets (Normalized)
 −33.88%14.51%−1.58%
Return on Equity (Normalized)
 −233.97%20.57%−7.14%
Return on Invested Capital (Normalized)
 −182.73%17.92%−4.76%
Return on Assets
RARE
NBIX
SRPT
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBfwjrnxdsLzly$566.6 Bil
VRTX
Vertex Pharmaceuticals IncCcdyvwlxHtsbbc$102.4 Bil
REGN
Regeneron Pharmaceuticals IncRhtpkbfXmzgsp$98.3 Bil
MRNA
Moderna IncGvxmdwmfQzrt$42.7 Bil
ARGX
argenx SE ADRGnvgtskGzx$22.2 Bil
BNTX
BioNTech SE ADRTmvcyljCczp$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncFfvzvgmxpBksjxy$18.6 Bil
BMRN
Biomarin Pharmaceutical IncRsvtmjyjFltmx$15.6 Bil
RPRX
Royalty Pharma PLC Class AZtgkyljsqqHnzrvnw$12.7 Bil
INCY
Incyte CorpJlvcvsyzwFwxdzm$11.8 Bil

Sponsor Center